35 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
modified, at least annually. Management must obtain the specific prior approval of the audit committee for each engagement of the independent registered … , in determining whether to grant approval of any type of non-audit service, or of any specific engagement to perform a non-audit service, is
whether
425
SYRS
Syros Pharmaceuticals Inc.
2 Sep 22
Business combination disclosure
4:03pm
,and$23.00 per share, and $11.00 per share, respectively
Moelis Engagement
Under the heading “The Merger—Opinion of Moelis & Company LLC … of $125,000 upon execution of the engagement letter with Moelis, and Moelis also became entitled to an opinion fee of $1,250,000 in connection
8-K
xvvjrf5 l1gnj
2 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
424B3
vvw1ehticb28v
8 Aug 22
Prospectus supplement
5:47pm
S-4
rvyvl
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
8-K
EX-10.1
6m0obb7byjqot2zqlnz
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.1
6c44rf6ohdnq
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
fucv0p
25 Feb 21
Regulation FD Disclosure
7:01am
424B5
zkls1
20 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
cls3m bxm1xe6t
19 Jan 21
Prospectus supplement for primary offering
4:06pm